KR20070032006A - Quinazolinedione derivatives as parp inhibitors - Google Patents

Abstract

The present invention provides compounds of formula (I), their use as PARP inhibitors and pharmaceutical compositions comprising said compounds of formula (I):

Wherein R ¹ , L ¹ , L ² , X, Y and Z have the meanings defined in the specification.

Description

QUINAZOLINEDIONE DERIVATIVES AS PARP INHIBITORS}

The present invention relates to an inhibitor of PARP and provides a compound and a composition containing the disclosed compound. The present invention also provides a method of using the disclosed PARP inhibitors, for example as a medicament.

Nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1) is a member of the PARP enzyme family. This growing family of enzymes includes, for example, PARPs such as PARP-1, PARP-2, PARP-3 and Vault-PARP; For example, it consists of TANKases, such as TANK-I, TANK-2, and TANK-3. PARP is also called poly (adenosine 5′-diphospho-ribose) polymerase or PARS (poly (ADP-ribose) synthase).

Tankyrase (TANK) has been identified as a component of the human telomeric complex. They have also been suggested to play a role in vesicle trafficking and can serve as a scaffold for proteins involved in various other cellular processes. Telomeres, which are important for chromosome maintenance and stability, are maintained by specific reverse transcriptases, which are terminal telomerases. TANK is a (ADP-ribose) transferase that has some properties of both signaling and cytoskeletal proteins. These include a PARP region that catalyzes the poly-ADP-ribosylation of a substrate protein that is a sterile alpha motif that shares a predetermined signal molecule and an ANK region containing 24 ankyrin repeat homologues for cytoskeleton protein ankyrin. The ANK region interacts with terminal repeat binding factor-1 (TRF-1), which is a terminal protein. Thus, these proteins are referred to as TRF1-interacting, ankyrin-associated ADP-ribose polymerases (TANKs).

One of the more characteristic functions of TANK is ADP-ribosylation of TRF-1. Human terminal function requires two terminal-specific DNA binding proteins, TRF-1 and TRF-2. TRF-2 protects the chromosomal end and TRF-1 adjusts the end length. ADP-ribosylation inhibits the ability of TRF-1 to bind to terminal DNA. This poly-ADP-ribosylation of TRF-1 opens the terminal complex to release TRF-1 from the terminal, allowing access to the terminal enzyme. Thus, TANK functions as a positive regulator of terminal length, allowing the extension of the terminal by the terminal enzyme.

PARP-1 is a major nucleoprotein of 116 kDa consisting of three regions, an N-terminal DNA binding region, an automutation region and a C-terminal catalytic region containing two zinc fingers. It is present in almost all eukaryotic cells. Enzymes synthesize poly (ADP-ribose), a branched polymer that can consist of more than 200 ADP-ribose units. Protein receptors of poly (ADP-ribose) are included directly or indirectly while maintaining DNA integrity. These histones, topoisomerase, DNA and RNA polymerase, DNA connection enzymes, and Ca ^{+ 2} - and a dependent endonuclease - and Mg ^{+ 2.} PARP proteins are expressed at high levels in many tissues, most notably the immune system, heart, brain and microbial-cell lines. There is minimal PARP activity under normal physiological conditions. However, DNA damage results in immediate activation up to 500-fold by PARP.

Among the many functions attributed to PARP, in particular PARP-1, its main role is to coordinate many DNA repair proteins as it facilitates DNA repair by ADP-ribosylation. As a result of PARP activation, the NAD ⁺ level drops significantly. Comprehensive PARP activation results in severe deficiency of NAD ⁺ in cells undergoing massive DNA damage. The short half-life of poly (ADP-ribose) results in a fast conversion speed. Once poly (ADP-ribose) is formed, it is rapidly degraded by the essentially active poly (ADP-ribose) glycohydrolase (PARG) together with phosphodiesterase and (ADP-ribose) protease. . PARP and PARG form a cycle that converts large amounts of NAD ⁺ into ADP-ribose. In less than one hour, over-stimulation of PARP can lower NAD ⁺ and ATP to less than 20% of normal levels. This scenario is particularly harmful during ischemia if oxygen deficiency has already dramatically reduced cellular energy output. Subsequent free radical production during reperfusion is believed to be a major cause of tissue damage. Some of the typical ATP drops in many organs during ischemia and reperfusion could lead to NAD ⁺ deficiency due to poly (ADP-ribose) conversion. Thus, PARP or PARG inhibition is expected to conserve cellular energy levels and thus enhance survival of ischemic tissues after injury.

Poly (ADP-ribose) synthesis is also involved in the induced expression of many genes essential for the inflammatory response. PARP inhibitors inhibit the production of macrophages, inducible nitric oxide synthase (iNOS) in P-type selectin and intercellular adhesion molecule-1 (ICAM-1) in endothelial cells. This activity underlies the potent anti-inflammatory effects exhibited by PARP inhibitors. PARP inhibition can reduce necrosis by preventing neutrophils from translocation and penetration into damaged tissue.

PARP is activated by damaged DNA fragments and, once activated, catalyzes attachment of up to 100 ADP-ribose units to various nuclear proteins, including histones and PARP itself. During major cellular stress, extensive activation of PARP can rapidly lead to cell damage or death through lack of energy conservation. Since four molecules of ATP are consumed every molecule of regenerated NAD ⁺ , NAD ⁺ is deficient by large amounts of PARP activation in an effort to resynthesize NAD ⁺ , so that ATP may also be deficient.

PARP activation has been reported to play an important role in both NMDA- and NO-induced neurotoxicity. This is demonstrated in cortical culture and hippocampal sections, where the prevention of toxicity correlates directly with the PARP inhibition potential. Thus, the potential role of PARP inhibitors in the treatment of neuropathic degenerative and head trauma is acknowledged, although the exact mechanism of its action has not yet been elucidated.

Likewise, infusion of PARP inhibitors alone has been demonstrated to reduce infarct size caused by ischemia and reperfusion of skeletal muscle or heart in rabbits. In these studies, a single infusion of 3-amino-benzamide (10 mg / kg) 1 minute before occlusion or 1 minute prior to reperfusion resulted in a similar reduction (32-42%) in infarct size in the heart while other PARPs. Inhibitor 1,5-dihydroxyisoquinoline (1 mg / kg) reduces infarct size to comparable levels (38-48%). These results can reasonably assume that the PARP inhibitor is to rescue the reperfusion injury or ischemic heart of skeletal muscle tissue in advance.

PARP activation also involves glutamate (via NMDA receptor stimulation), reactive oxygen intermediates, amyloid β-proteins, N-methyl-4-phenyl-1,2,3, which are involved in pathologies such as stroke, Alzheimer's disease and Parkinson's disease. It can be used as a treatment for damage after neurotoxic seizures due to exposure to either inducer such as 6-tetrahydropyridine (MPTP) or its active metabolite N-methyl-4 phenylpyridine (MPP ⁺ ). Other studies are in vitro ( in In vitro studies on the role of PARP activation in bovine granulocytes and MPTP neurotoxicity. Excessive nerve exposure to glutamate, which acts as a predominant central nervous system neurotransmitter and also acts on the N-methyl D-aspartate (NMDA) receptor and other subtype receptors, is often a result of stroke or other neurodegenerative disease processes. Happens most often. Oxygen deprived neurons release large amounts of glutamate during ischemic brain injury, such as during stroke or heart attack. This excess release of glutamate then leads to overstimulation (excitility) of N-methyl-D-aspartate (NMDA), AMPA, Kainate and MGR receptors, which open ion channels to neurons US-controlled ion flow that results in the over-stimulation (for example, into the cells Ca ² + and Na ^+, K ⁺ out of the cell) allow for. Overstimulated neurons secrete more glutamate, creating a feedback loop or domino effect, ultimately leading to cell damage or death through the production of proteases, lipases and free radicals. Over-activation of glutamate receptors can affect epilepsy, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, schizophrenia, chronic pain, ischemia, neuronal loss after hypoxia, hypoglycemia, ischemia, trauma and nerve damage Has been implicated in a variety of neurological diseases and conditions, including. Glutamate exposure and stimulation have also been implicated as criteria for obsessive compulsive disorder, especially drug dependence. Evidence shows that many animal species, as well as glutamate receptor antagonists (ie, compounds that block glutamate binding to or activating its receptors) in cerebral cortical cultures treated with glutamate or NMDA, which block nerve damage after vascular stroke Includes findings in Attempts to prevent excitatory toxicity by blocking NMDA, AMPA, catenate and MGR receptors prove difficult because each receptor has multiple sites to which glutamate can bind, thus preventing the binding of glutamate to all receptors. It was difficult to find an effective mix of antagonists or breakthrough antagonists that enabled testing of this theory. In addition, many compositions that are effective for blocking receptors are also toxic to animals. As such, no effective treatment for glutamate abnormalities is currently known. Stimulation of NMDA receptors by glutamate activates the enzyme neuronal nitric oxide synthase (nNOS), which, for example, leads to the formation of nitric oxide (NO) and also mediates neurotoxicity. NMDA neurotoxicity can be prevented by treatment with nitric oxide synthase (NOS) inhibitors or through targeted genetic disruption of nNOS in vitro.

Another use of PARP inhibitors is the treatment of peripheral nerve damage, and the resulting pathological pain symptoms are known as neuropathic pain, such as caused by chronic stenosis damage (CCI) of the common sciatic nerve, and cytoplasmic and nuclear hyperpigmentation (so-called Synaptic transmutation of the spinal dorsal horn, characterized by "dark" neurons) occurs.

There is also evidence that it is useful for the treatment of inflammatory bowel diseases such as colitis. Specifically, colitis is induced in rats by in vitro administration of hapten trinitrobenzene sulfonic acid in 50% ethanol. Treated rats received 3-aminobenzamide, a specific inhibitor of PARP activity. Inhibition of PARP activity reduces the inflammatory response and restores the shape and energy state of the distal colon.

Further evidence suggests that PARP inhibitors are useful for treating arthritis. PARP inhibitors also appear to be useful for treating diabetes. PARP inhibitors have been shown to be useful for treating endotoxin shock or septic shock.

PARP inhibitors also include skin aging, Alzheimer's disease, atherosclerosis, osteoarthritis, osteoporosis, muscular dystrophy, skeletal muscle degeneration, including replication aging, age-related muscle degeneration, immune aging, ADDS, and other immune aging disorders. Extending the lifespan and proliferative capacity of cells, including the treatment of diseases of; And it has been used to change the gene expression of senescent cells.

PARP inhibitors, such as 3-amino benzamide, are also known to affect overall DNA repair in response to, for example, hydrogen peroxide or ionizing radiation.

The central role of PARP in the repair of DNA chromosomal damage is in particular by direct ionization radiation following enzymatic repair of DNA lesions caused by methylating agents, isomerase I inhibitors and other chemotherapeutic agents such as cisplatin or bleomycin. Or indirectly, it is well established. Various studies using “knockout” mice, trans-dominant inhibition model (overexpression of DNA-binding regions), antisense and small molecular weight inhibitors have been shown to play a role in PARP in post-injury repair and cell survival. Prove that. Inhibition of PARP enzymatic activity needs to lead to an increase in the sensitivity of tumor cells towards DNA damage treatment.

PARP inhibitors are effective for radiosensitization of (hypoxic) tumor cells and also affect the several DNA damage signaling pathways by their ability to prevent recombination of DNA chromosome damage, thereby allowing tumor cells to undergo It has been reported to be effective in preventing recovery from potential lethal and semi-larval injury.

PARP inhibitors have been used to treat cancer. U.S. Patent No. 5,177,075 also discloses several inoquinolines used to enhance the lethal effect of ionizing radiation or chemotherapeutic agents on tumor cells. Weltin et al., "Effect of 6 (5-Phenanthridinone), an Inhibitor of Poly (ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncol. Res., 6: 9, 399-403 (1994) disclose inhibition of PARP activity, decreased proliferation of tumor cells and significant synergistic effects when tumor cells are co-treated with alkylating drugs.

A review of the state of the art in the art is given by Li and Zhang in "IDrugs 2001, 4 (7): 804-812", by Ame et al. In "Bioassays 2004, 26: 882-883" and by Nguewa et al. "Progress in Biophysic". & Molecular Biology 2005, 88: 143-172 ".

However, there is a continuing need for effective and potent PARP inhibitors, especially PARP-1 inhibitors that produce minimal side effects. The present invention provides compounds, compositions and methods for inhibiting PARP activity to treat cancer resulting from, for example, cell damage or death resulting from necrosis or apoptosis and / or to prevent cell, tissue and / or organ damage. to provide. The compounds and compositions of the present invention are particularly used to enhance the efficacy of chemotherapy and radiation therapy where the primary effect of treatment is to cause DNA damage in target cells.

Conventional Background

EP 1036073, published June 17, 1999, discloses substituted quinazolinedione derivatives. The described compounds have gastrointestinal relief. Especially the compound 1- [1-[(2S) -2-[(2R) -3,4-dihydro-2H-1-benzopyran-2-yl] -2-hydroxyethyl] -4-piperidinyl ] -2,4- (1H, 3H) -quinazolindione (compound number 9 of the present application) is disclosed:

.

.

EP 13612, published November 11, 1983, discloses substituted piperidinylalkylquinazoline derivatives. This compound is a serotonin-antagonist. In particular, compound 1- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (compound number 10 of the present application),

1- [3- [4- (4-fluorobenzoyl) -1-piperidinyl] propyl] -2,4- (1H, 3H) -quinazolindione (compound no. 11 of the present application),

3- [2- [4- (4-chlorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (compound number 12 of the present application)

3- [2- [4-[(4-fluorophenyl) hydroxymethyl] -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (compound number 13 of the present application) ) Is disclosed.

Description of the Invention

The present invention relates to compounds of formula (I), N-oxide forms, pharmaceutically acceptable addition salts or stereochemically isomeric forms thereof:

In the formula,

또는

이고; X가

이면 Y는

이며;X is each independently

or

ego; X

Y is

Is;

또는

이고; 단 X가

인 경우 Y가

인 것은 제외하며; Y is each independently

or

ego; Only X

If is Y

Except

L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from;

L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl -, -C (O) -C _1-6 alkanediyl - or - C _{1 - 6} alkanediyl -C (O) - it is a divalent radical selected from;

R ¹ is hydrogen or hydroxy;

Z is hydrogen or a radical selected from formulas (a-1) to (a-5):

Wherein, R ² are each independently hydrogen, halo or C _{1 - 6} is selected from alkyl;

Provided that 1- [1-[(2S) -2-[(2R) -3,4-dihydro-2H-1-benzopyran-2-yl] -2-hydroxyethyl] -4-piperidinyl ] -2,4- (1H, 3H) -quinazolindione,

1- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione,

1- [3- [4- (4-fluorobenzoyl) -1-piperidinyl] propyl] -2,4- (1H, 3H) -quinazolindione, 3- [2- [4- (4- Chlorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione and

3- [2- [4-[(4-fluorophenyl) hydroxymethyl] -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione is not included.

When Z is a heterocyclic ring system comprising a -CH _2- , -CH = or -NH- moiety at any time the substituent R ² and / or the remainder of the molecule may be attached to a carbon and / or nitrogen atom, in which case One or both hydrogen atoms are replaced.

In the compounds of formula (I), the quinazolindione moiety can be attached to the remainder of the molecule on the -NH- moiety in the 1- or 3-position, in which one hydrogen atom is replaced.

The compounds of formula (I) may also exist in their tautomeric forms. Such forms are not expressly indicated in the above formula but are included within the scope of the present invention.

Many terms used in the above definitions and the following descriptions are described below. These terms may be used as they are or as compound terms.

As used in the definitions above and below, halo is a generic name for fluoro, chloro, bromo and iodo; C _{1 - 6} alkyl, for example methyl, ethyl, propyl, butyl, pentyl, hexyl, 1-methylethyl, 2-methylpropyl, 2-methylbutyl, having from 1 to 6 carbon atoms such as 2-methyl-pentyl Defining straight and branched saturated hydrocarbon radicals; C _{1 -6} alkanediyl thing, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butane-diyl, pentane-1,5-diyl, such as 1,6-diyl 1 Divalent straight and branched chain saturated hydrocarbon radicals having from 6 to 6 carbon atoms and their branched isomers such as 2-methylpentanediyl, 3-methylpentanediyl, 2,2-dimethylbutanediyl, 2,3-dimethylbutanediyl, and the like. Define.

The term "pharmaceutically acceptable salts" means pharmaceutically acceptable acid or base addition salts. Pharmaceutically acceptable acid or base addition salts as described above are meant to include therapeutically active non-toxic acid and non-toxic base addition salt forms from which the compound of formula (I) may be formed. Compounds of formula (I) having basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with the appropriate acid. Suitable acids include, for example, hydrochloric acid such as hydrochloric acid or hydrobromic acid; Sulfuric acid; nitric acid; Inorganic acids such as phosphoric acid; Or for example acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid (ie butanediic acid), maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, Organic acids such as benzenesulfonic acid, p-toluenesulfonic acid, cyclic acid, salicylic acid, p-aminosalicylic acid and pamoic acid.

Compounds of formula (I) having acidic properties can be converted to their pharmaceutically acceptable base addition salts by treating their acid forms with the appropriate organic or inorganic salts. Suitable base salt forms include, for example, alkali metal salts such as ammonium salts such as lithium salts, sodium salts, potassium salts, magnesium salts, calcium salts and alkaline earth metal salts such as benzatin salts, N-methyl-D- Salts with organic salts, such as glucamine salt and hydravamin salt, For example, salts with amino acids, such as arginine and lysine, are included.

The term acid or base addition salt also includes hydrate and solvent addition forms in which the compound of formula (I) may be formed. Examples of such forms are, for example, hydrates, alcoholates and the like.

As used below, the stereochemically isomeric forms of the compounds of formula (I) may be possessed by compounds of formula (I), which consist of the same atoms having different three-dimensional structures that are bound by the same sequence of bonds but are incompatible Define all possible compounds. Unless otherwise stated or indicated, the chemical nomenclature of a compound encompasses a mixture of all possible stereochemically isomeric forms that the compound may possess. The mixture may comprise both diastereomers and / or enantiomers of the basic molecular structure of the compound. All stereochemically isomeric forms of the compounds of formula (I) are intended to be included within the scope of the invention, whether in pure form or in admixture with one another.

The N-oxide form of a compound of formula (I) is a compound of formula (I) in which one or several nitrogen atoms are oxidized to so-called N-oxides, in particular one or more of piperidine- or piperazine nitrogen It is meant to include an oxidized N-oxide.

Whenever used below, the term "compound of formula (I)" is meant to include N-oxide forms, pharmaceutically acceptable acid or base addition salts, and all stereochemically isomeric forms.

The compounds disclosed in EP 1036073 have gastrointestinal relief. In particular, EP 1036073 discloses compound 1- [1-[(2S) -2-[(2R) -3,4-dihydro-2H-1-benzopyran-2-yl] -2-hydroxyethyl] -4-piperidinyl] -2,4- (1H, 3H) -quinazolindione (compound number 9 of the present application) is disclosed. In addition, the compound in EP 13612 is a serotonin-antagonist. In particular, 1- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (Compound No. 10 of the present application),

1- [3- [4- (4-fluorobenzoyl) -1-piperidinyl] propyl] -2,4- (1H, 3H) -quinazolindione (compound no. 11 of the present application),

3- [2- [4- (4-chlorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (compound number 12 of the present application)

3- [2- [4-[(4-fluorophenyl) hydroxymethyl] -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione (compound number 13 of the present application) ) Is disclosed.

Unexpectedly, the compounds of the present invention were found to exhibit PARP inhibitory activity.

The first group of compounds of interest consists of compounds of formula (I) to which one or more of the following constraints apply:

또는

임;a) each X is independently

or

being;

또는

임; b) Y is each independently

or

being;

c) L ¹ is a direct bond or -C _{1 - 6} alkanediyl-Im 2-valent radical selected from;

d) L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl - or -C (O) -C _{1 - 6} alkanediyl - Divalent radical selected from;

e) R ¹ is hydrogen or hydroxy;

f) Z is hydrogen or a radical selected from (a-1), (a-2), (a-3), (a-4) or (a-5);

g) R ² are each independently hydrogen, halo or C _{1 - 6} alkyl selected from.

The second group of compounds of interest consists of compounds of formula (I) to which one or more of the following constraints apply:

a) L ² is a bond, or -C _{1 - 6} alkanediyl - or -C (O) -C _{1 - 6} alkanediyl-Im divalent radical selected from;

b) Z is hydrogen or a radical selected from (a-1), (a-4) or (a-5).

The third group of compounds of interest consists of compounds of formula (I) to which one or more of the following constraints apply:

임;a) X is each

being;

임; b) Y is each

being;

c) L ¹ is a direct bond;

d) L ² is a direct bond;

e) R ¹ is hydrogen;

f) Z is hydrogen.

또는

이고; Y가 각각 독립적으로

또는

이고; L¹이 직접 결합 또는 -C_{1 - 6}알칸디일-로부터 선택된 2가 라디칼이고; L²가 직접 결합, 또는 카보닐 혹은 -C_{1 - 6}알칸디일-로부터 선택된 2가 라디칼이며; R¹이 수소 또는 하이드록시이고; Z가 수소 또는 화학식 (a-1), (a-2), (a-3), (a-4) 또는 (a-5)로부터 선택된 라디칼이고; R²가 각각 독립적으로 수소, 할로 또는 C_{1 - 6}알킬로부터 선택되는 화학식 (I)의 화합물로 구성된다.Preferred group of compounds is that X is each independently

or

ego; Y each independently

or

ego; L ¹ is a bond or -C _{1 - 6} alkanediyl - a divalent radical selected from; L ² is a direct bond, or a carbonyl, or -C _{1 - 6} alkanediyl-is a bivalent radical selected from; R ¹ is hydrogen or hydroxy; Z is hydrogen or a radical selected from formulas (a-1), (a-2), (a-3), (a-4) or (a-5); Consists of compounds of formula (I) is selected from _{6-alkyl -} R ² are each independently hydrogen, halo, or C _1.

이고; Y가 각각

이며; L¹이 직접 결합이고; L²가 직접 결합이며; R¹이 수소이고; Z가 수소인 화학식 (I)의 화합물로 구성된다.More preferred group of compounds are each X is

ego; Y is each

Is; L ¹ is a direct bond; L ² is a direct bond; R ¹ is hydrogen; It consists of a compound of formula (I) wherein Z is hydrogen.

Most preferred compound is compound number 1:

Compounds of formula (I) can be prepared according to the general methods described in EP 1036073 and EP 13612. Some of the starting materials and intermediates are commercially known compounds or may be prepared according to conventional reaction procedures generally known in the art.

Some methods of preparation will be described in detail below. Other methods of obtaining the final compound of formula (I) are described in the Examples.

인 화학식 (I)의 화합물(본 명세서에서 화학식 (I-a)의 화합물이라 칭함)은 화학식 (II)의 중간체를 화학식 (III)의 중간체와 반응시킴으로써 제조될 수 있고, 상기 화학식 (III) 중, W는 예를 들어, 플루오로, 클로로, 브로모 또는 아이오도 등의 할로, 또는 예를 들어, 메틸설포닐옥시, 4-메틸페닐설포닐옥시 등의 설포닐옥시 라디칼 등의 적절한 이탈기이다. 상기 반응은 예를 들어 메탄올, 에탄올, 2-메톡시-에탄올, 프로판올, 부탄올 등의 알코올류; 예를 들어 4,4-디옥산, 1,1'-옥시비스프로판 등의 에테르류; 또는 4-메틸-2-펜타논 등의 케톤류; N,N-디메틸포름아마이드; 니트로벤젠 등과 같은 반응에 불활성인 용매 중에서 수행될 수 있다. 예를 들어 트리에틸아민 혹은 탄산 나트륨 등의 알칼리 혹은 알칼리토금속 탄산염 혹은 탄산수소염과 같은 적절한 염기의 첨가는 반응 과정 중에서 해리되는 산을 픽업하는 데 이용될 수 있다. 반응을 촉진시키기 위해 예를 들어 나트륨 혹은 칼륨 요드화물 등의 적절한 금속 요드화물을 소량 첨가할 수 있다. 교반은 반응 속도를 높일 수 있다. 또, 반응은 실온과 반응 혼합물의 환류 온도 사이의 범위의 온도에서 적절하게 수행될 수 있고, 필요한 경우, 반응은 승압에서 수행될 수 있다.X

A compound of formula (I), referred to herein as a compound of formula (Ia), may be prepared by reacting an intermediate of formula (II) with an intermediate of formula (III), wherein in formula (III) Is a suitable leaving group such as halo such as fluoro, chloro, bromo or iodo, or a sulfonyloxy radical such as, for example, methylsulfonyloxy, 4-methylphenylsulfonyloxy and the like. The reaction is, for example, alcohols such as methanol, ethanol, 2-methoxy-ethanol, propanol and butanol; Ethers such as 4,4-dioxane and 1,1'-oxybispropane; Or ketones such as 4-methyl-2-pentanone; N, N-dimethylformamide; It may be carried out in a solvent inert to the reaction, such as nitrobenzene. For example, the addition of a suitable base such as alkali or alkaline earth metal carbonate or hydrogen carbonate such as triethylamine or sodium carbonate can be used to pick up the acid dissociated during the reaction. Small amounts of suitable metal iodide, such as for example sodium or potassium iodide, may be added to facilitate the reaction. Stirring can speed up the reaction. In addition, the reaction can be appropriately carried out at a temperature in the range between room temperature and the reflux temperature of the reaction mixture, and if necessary, the reaction can be carried out at elevated pressure.

인 화학식 (I)의 화합물(본 명세서에서 화학식 (I-b)의 화합물이라 칭함)은 화학식 (IV)의 중간체를 화학식 (V)의 중간체(식 중, W는 전술한 바와 같음)와 반응시킴으로써 제조될 수 있다.In a similar manner, Y is

A compound of formula (I), referred to herein as a compound of formula (Ib), may be prepared by reacting an intermediate of formula (IV) with an intermediate of formula (V), wherein W is as defined above Can be.

The compounds of formula (I) may be converted to one another via reactions or functional group transformations known in the art. Some of these transformations are already described above. Other examples include hydrolysis of the carboxylic ester to the corresponding carboxylic acid or alcohol; Hydrolysis of the amide to the corresponding carboxylic acid or amine; Hydrolysis of the nitrile to the corresponding amide; Amino groups on imidazole or phenyl may be substituted with hydrogen by diazotization reactions known in the art, followed by substitution of diazo groups with hydrogen; Alcohols can be converted to esters and ethers; Primary amines can be converted to secondary or tertiary amines; Double bonds may be hydrogenated with corresponding single bonds; The iodo radicals on the phenyl group can be converted to ester groups by the insertion of carbon monoxide in the presence of a suitable palladium catalyst.

The present invention relates to a compound of formula (I) for use as a medicament.

The compounds of the present invention have PARP inhibitory properties as can be seen from the experimental section below.

The term "PARP" is used herein to mean a protein having poly-ADP-ribosylation activity. Within the meaning of this term, PARP includes all proteins encoded by the parp gene, variants thereof, and modified slice proteins thereof. In addition, as used herein, the term “PARP” includes PARP analogs, homologs and analogs of other animals.

The term "PARP" includes, but is not limited to PARP-1. Within the meaning of this term PARP-2, PARP-3, Vault-PARP (PARP-4), PARP-7 (TiPARP), PARP-8, PARP-9 (Bal), PARP-10, PARP-11, PARP -12, PARP-13, PARP-14, PARP-15, PARP-16, TANK-1, TANK-2 and TANK-3 can be included.

Compounds that inhibit both PARP-1 and tankyrase 2 may have beneficial properties in enhancing growth inhibitory activity in cancer cells.

The invention also contemplates the use of a compound in the manufacture of a medicament for treating any of the diseases and disorders in the animals described herein, wherein the compound is a compound of formula (I), an N-oxide form thereof , Pharmaceutically acceptable addition salts or stereochemically isomeric forms:

In the formula,

또는

이고; X가

이면 Y는

이며;X is each independently

or

ego; X

Y is

Is;

또는

이고; 단 X가

인 경우 Y가

인 것은 제외하며; Y is each independently

or

ego; Only X

If is Y

Except

L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from;

L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl -, -C (O) -C _1-6 alkanediyl - or - C _{1 - 6} alkanediyl -C (O) - it is a divalent radical selected from;

R ¹ is hydrogen or hydroxy;

Z is hydrogen or a radical selected from formulas (a-1) to (a-5):

Wherein, R ² are each independently hydrogen, halo or C _{1 - 6} is selected from alkyl.

The compounds of the present invention can be used as reference compounds or marker compounds, in view of their PARP binding properties, where one of the atoms of the molecule can be substituted, for example, with a radioisotope.

To prepare a pharmaceutical composition of the invention, an effective amount of a specific compound in the form of a base or acid addition salt as an active ingredient is formulated in intimate mixture with a pharmaceutically acceptable carrier, wherein the carrier is in accordance with the form of preparation desired for administration. It can take a variety of forms. These pharmaceutical compositions are preferably in single dose form suitable for parenteral infusion or for oral, rectal and transdermal administration. For example, when preparing the composition in oral dosage form, for example, oral liquid preparations such as suspensions, syrups, elixirs and solutions, water, glycols, oils, alcohols and the like; Or in the case of powders, pills, capsules and tablets, useful pharmaceutical media such as solid carriers such as starch, sugar, kaolin, glidants, binders, disintegrants and the like can be used. Because of their ease of administration, tablets and capsules represent the most advantageous oral unit dosage forms, in which case solid pharmaceutical carriers are explicitly used. In the case of parenteral compositions, the carrier may, for example, contain other ingredients which aid in dissolution, but usually at least mostly contain sterile water. For example, an injectable solution may be prepared using a carrier including saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared using appropriate liquid carriers, suspending agents and the like. In a composition suitable for transdermal administration, the carrier optionally comprises a penetration enhancer and / or a suitable wetting agent, optionally in combination with a small amount of suitable additives which do not have a very harmful effect on the skin. Such additives may facilitate skin administration and / or may help to prepare the necessary compositions. These compositions can be administered in a variety of ways, for example as a transdermal patch, as a drop or as an ointment. It is particularly advantageous to formulate the pharmaceutical composition in dosage units to facilitate administration and uniformity of dosage. It is particularly advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein and in the claims means physically discrete units suited as unitary dosages, each containing a predetermined amount of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms include tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoon preparations, large spoon dose preparations, and the like, and these It is a segregated multiple of.

The compounds of the present invention can treat or prevent tissue damage resulting from cell damage or death resulting from necrosis or apoptosis; Improve nervous system or cardiovascular tissue damage including focal ischemia, myocardial infarction and reperfusion injury; To treat a variety of diseases and conditions caused or aggravated by PARP activity; Can prolong or increase the lifespan or proliferation of cells; Alter gene expression of senescent cells; Cells can be radiosensitized and / or chemosensitized. In general, inhibition of PARP activity does not cause energy loss in cells, and in the case of neurons, prevents irreversible depolarization of neurons, thus providing neuroprotection.

For this reason, the present invention also inhibits PARP activity; Treating or preventing tissue damage resulting from cell damage or death due to necrosis or apoptosis; To validate neuronal activity not mediated by NMDA toxicity; To validate neuronal activity mediated by NMDA toxicity; Treating nerve tissue damage resulting from ischemia and reperfusion injury, neurological disease and neurodegenerative disease; Prevent or treat vascular stroke; Treating or preventing cardiovascular diseases; Degenerative diseases of skeletal muscle, including age-related muscle degeneration, AIDS and other immune aging diseases, inflammation, gout, arthritis, atherosclerosis, cachexia, cancer, replicative aging, diabetes, head trauma, inflammatory bowel disease (colitis and Crohn's disease) And other diseases such as muscle regression axis, osteoarthritis, osteoporosis, chronic and / or acute pain (such as neuropathic pain), renal failure, retinal ischemia, septic shock (such as endotoxin shock), and skin aging To cure disease; Prolong the lifespan and proliferative capacity of the cells; Alter gene expression of senescent cells; The present invention relates to a method of administering a therapeutically effective amount of said compound in an amount sufficient to chemically and / or radiosensitize (hypoxic) tumor cells. The invention also relates to treating diseases and disorders in animals comprising administering to the animal a therapeutically effective amount of said compound.

In particular, the present invention relates to methods of treating, preventing or inhibiting nervous system diseases in an animal comprising administering to the animal a therapeutically effective amount of said compound. Nervous system diseases include peripheral neuropathy, traumatic brain injury, body damage to the spinal cord, stroke associated with brain injury, stroke associated with brain injury, focal ischemia, total ischemia, reperfusion injury, demyelinating diseases and neurodegeneration Selected from the group consisting of disorders.

The present invention relates to compounds of formula (I) which inhibit PARP activity to treat, prevent or inhibit tissue damage resulting from cell damage or death by necrosis or apoptosis, or to treat, prevent or inhibit neurological diseases in animals. The use of is also assumed.

The term "preventing neurodegeneration" refers to preventing neurodegeneration in patients newly diagnosed with neurodegenerative disease or the likelihood of developing a new degenerative disease, and having or suffering from a neurodegenerative syndrome. The ability to further prevent neurodegeneration of the patient.

As used herein, the term "treatment" encompasses any treatment of an animal, particularly a human, and / or disease, and (i) to a subject susceptible to, but not yet diagnosed with, the disease. Preventing the disease and / or disease from occurring; (ii) inhibiting said disease and / or disease, ie preventing its development; (iii) alleviating the disease and / or disease, ie causing regression of the disease and / or disease.

As used herein, the term "radiation sensitizer" means a molecule administered to an animal in a therapeutically effective amount, preferably to increase the cell's sensitivity to ionizing radiation and / or to promote treatment of a disease treatable with ionizing radiation. It is defined as a low molecular weight molecule. Diseases treatable with ionizing radiation include neoplastic diseases, benign and malignant tumors and cancer cells. Ionizing radiation treatment of other diseases not listed here is also contemplated by the present invention.

As used herein, the term “chemical sensitizer” refers to a molecule, preferably a molecule, administered to an animal in a therapeutically effective amount to increase the sensitivity of the cells to chemotherapy and / or to promote the treatment of a disease treatable with chemotherapy. It is defined as a low molecular weight molecule. Chemotherapy treatable diseases include neoplastic diseases, benign and malignant tumors and cancer cells. Chemotherapy treatment of other diseases not listed here is also contemplated by the present invention.

The compounds, compositions and methods of the invention are particularly useful for treating or preventing tissue damage resulting from cell death or damage by necrosis or apoptosis.

Compounds of the invention may be "anticancer agents" and the term also encompasses "antitumor cell proliferative agents" and "antineoplastic agents". For example, the methods of the present invention include ACTH-producing tumors, acute lymphocytic leukemia, acute nonlymphoid leukemia, adrenal cortex cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, chronic lymphoma leukemia, chronic myeloid leukemia, colorectal cancer, skin Sexual T-cell lymphoma, endometrial cancer, esophageal cancer, Ewing's sarcoma, gallbladder cancer, hairy cell leukemia, head and neck cancer, Hodgkin's lymphoma, Kaposi's sarcoma, kidney cancer, liver cancer, lung cancer (small and / or non-small cell), malignant peritoneum Exudation, malignant pleural effusion, melanoma, mesothelioma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, osteosarcoma, ovarian cancer, ovarian (germ cell) cancer, prostate cancer, pancreatic cancer, penile cancer, retinoblastoma, skin cancer, soft tissue sarcoma, Chemosensitizing and / or radiation sensitizing tumor cells in cancers such as squamous cell carcinoma, gastric cancer, testicular cancer, thyroid cancer, trophoblastic neoplasia, uterine cancer, vaginal cancer, vulvar cancer and Wilm's tumor Useful for Do

Thus, the compounds of the present invention may be used as "radiation sensitizers" and / or "chemical sensitizers".

Radiation sensitizers are known to increase the sensitivity of cancer cells to the toxic effects of ionizing radiation. Several mechanisms for the mode of action of radiation sensitizers have been proposed in the literature, such as hypoxic cell radiation sensitizers that mimic oxygen or instead behave like bioreducers under hypoxia (eg, 2-nitroimi) Dazole compounds, and benzotriazine dioxide compounds); Non-oxygen cell radiation sensitizers (eg, halogenated pyrimidines) may be analogs of DNA bases, preferentially incorporated into the DNA of cancer cells, and thus promote radiation-induced destruction of DNA molecules and / or normal DNA Prevent recovery mechanisms; Potential mechanisms of various other actions have been assumed for radiation sensitizers in the treatment of diseases. Many cancer treatment protocols currently use radiation sensitizers associated with x-ray radiation. Examples of x-ray activated radiation sensitizers include metronidazole, misnidazole, desmethylmisonidazole, pimonidazole, ethandiazole, nimorazol, mitomycin C, RSU 1069, SR 4233, EO9, RB 6145, nicotinamide , 5-bromodeoxyuridine (BUdR), 5-iododeoxyuridine (IUdR), bromodeoxytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and the above therapeutic conditions Effective analogs and derivatives include, but are not limited to these. Photodynamic therapy (PDT) of cancer uses visible light as a radioactive activator of sensitizers. Examples of photodynamic radiation sensitizers include hematoporphyrin derivatives, photoprins, benzoporphyrin derivatives, tin thioporphyrins, pheboride-a, bacteriochlorophyll-a, naphthalocyanines, phthalocyanines, zinc phthalocyanines, and therapies described above. Phase effective analogs and derivatives, but are not limited to these.

Radiation sensitizers can be administered in conjunction with a therapeutically effective amount of one or more other compounds, including compounds that promote incorporation of the radiation sensitizer into target cells; Compounds which control the influx of therapeutics, nutrients and / or oxygen into target cells; Radiation therapy acting on tumors; Or other therapeutically effective compounds for treating cancer or other diseases. Examples of additional therapeutic agents that may be used in connection with radiation sensitizers include 5-fluorouracil, leukoborin, 5'-amino-5'deoxythymidine, oxygen, carbogen, erythrocyte transfusion, perfluorocarbons (e.g., For example, Fluosol 10 DA), 2,3-DPG, BW12C, calcium channel blocker, pentoxifylline, antiangiogenic compounds, hydrazines, and LBSOs may be mentioned, but are not limited to these. Examples of chemotherapeutic agents that may be used in connection with radiation sensitizers include adriamycin, camptothecin, carboplatin, cisplatin, downorubisin, docetaxel, doxorubicin, interferon (alpha, beta, gamma), interleukin 2, irinotecan , Paclitaxel, topotecan, and therapeutically effective analogs and derivatives thereof, but are not limited to these.

Chemosensitizers can be used in conjunction with a therapeutically effective amount of one or more other compounds, examples of which include compounds that promote the incorporation of a chemical sensitizer into target cells; Compounds which control the influx of therapeutics, nutrients and / or oxygen into target cells; Chemotherapeutic agents acting on tumors or other therapeutically effective compounds for treating cancer or other diseases. Examples of additional therapeutic agents that may be used in connection with chemosensitizers include, but are not limited to, methylating agents, topoisomerase I inhibitors and other chemotherapeutic agents such as cisplatin and bleomycin.

The compounds of formula (I) may also be used to detect or identify PARP, in particular PARP-1 receptor. For this purpose the compounds of formula (I) can be labeled. The label may be selected from the group consisting of radioisotopes, spin labels, antigen labels, enzyme labeled fluorescent or chemiluminescent groups.

One skilled in the art can easily determine the effective amount from the test results presented below. In general, an effective amount is assumed to be 0.001 mg / kg to 100 mg / kg body weight, in particular 0.005 mg / kg to 10 mg / kg body weight. It is appropriate to administer the required dose in two, three, four or more sub doses at appropriate intervals throughout the day. The subdose may be formulated as a unit dosage form containing, for example, 0.05 to 500 mg, in particular 0.1 mg to 200 mg of active ingredient per unit dosage form.

Examples of the present invention are illustrated below.

Experimental part

Hereinafter, "DCM" is defined as dichloromethane, "DIPE" is defined as diisopropyl ether, "DMF" is defined as N, N-dimethylformamide, "EtOH" is defined as ethanol, "MeOH "Is defined as methanol," MEK "is defined as methylethylketone," TEA "is defined as triethylamine and" THF "is defined as tetrahydrofuran.

A. Preparation of Intermediate Compounds

Example  A1

Preparation of Intermediate 1

2-[[1- (phenylmethyl) -4-piperidinyl] amino] -benzamide (0.03 mol) and 1,1'-carbonylbis-1H-imidazole (0.033) in dimethylacetamide (25 mL) mol) mixture was stirred and refluxed for 5 hours, then excess 1,1'-carbonylbis-1H-imidazole (0.003 mol) was added and the reaction mixture was stirred and refluxed overnight. The mixture was poured into water (300 mL) and the precipitate obtained was filtered off, washed with water and DIPE and dried (9.1 g-91% obtained). Next, a part was crystallized from DMF and water, and finally the desired product was recovered to obtain 0.8 g of intermediate 1 having a melting point of 233.5 ° C.

B. Preparation of Final Compound

Example  B1

Preparation of Compound 1

Intermediate 1 (0.15 mol) in THF (250 mL) and MeOH (250 mL) was hydrogenated in a Parr-device with 10% Pd / C (5 g) as catalyst. After occlusion of H ₂ (1 equivalent), the catalyst was filtered off to obtain filtrate (I) and the remaining precipitate on the filter. The precipitate was stirred in boiling hydroxyacetone and the mixture was filtered under warming. This filtrate was combined with the filtrate (I) and the mixture was evaporated. The residue was stirred in water, then NH ₄ OH was added and the mixture was stirred with trichloromethane for 1 hour. The precipitate was filtered off and dried to give 31 g (84%) of compound 1 having a melting point of 253.7 ° C.

Example  B2

Preparation of Compound 2

Compound 1 (0.038 mol) in 2-methoxy-ethanol (150 mL) was stirred until completely dissolved, then 1- (4-fluorophenyl) -4- in 2-methoxy-ethanol (10 mL) A solution of iodo-1-butanone (0.019 mol) was added dropwise under warming (precipitation occurred). The reaction mixture was stirred and refluxed for 1.5 hours. The precipitate was filtered off and the filtrate was evaporated. The residue was purified on silica gel (eluent: CHCH ₃ / MeOH 90/10) on a glass filter. The product fractions were recovered and the solvent was evaporated. The residue was crystallized from 2-propanol and the precipitate obtained was recovered and dried to give 2.3 g (29%) of compound 2 having a melting point of 195 ° C.

Example  B3

Preparation of Compound 3

1- (3-Chloropropyl) -2,4 (1H, 3H) -quinazolindione (0.015 mol), 3- (4-piperidinyl) -1H in 4-methyl-2-pentanone (150 mL) -A mixture of indole (0.015 mol) and sodium carbonate (0.030 mol) was stirred and refluxed for 24 hours, then the reaction mixture was cooled and water was added. The separated organic layer was dried and the solvent was evaporated. The residue was purified by column chromatography on silica gel (eluent: CHCl ₃ / CH ₃ OH 95/5). The product fractions were recovered and the solvent was evaporated. The residue was crystallized from EtOH, and the obtained precipitate was recovered to give 2 g (33%) of compound 3 having a melting point of 216.8 ° C.

Table 1 below lists the compounds prepared according to one of the above examples (in Table, Co. No. means compound number, Ex. Means Example, mp. Means melting point).

Pharmacological Example

PARP For -1 inhibitory activity In vitro Flash  Metric (Essay) (" SPA ")

Compounds of the invention are based on SPA technology (owned by Amersham Pharmacia Biotech) in vitro ( in in vitro ) assays.

In principle, the assay relies on well-established SPA technology for the detection of poly (ADP-ribosyl) ation of biotinylated target proteins, ie histones. This ribosylation was induced using nicked DNA activated PARP-1 enzyme and [ ³ H] -nicotinamide adenine dinucleotide ([ ³ H] -NAD ⁺ ) as ADP-ribosyl donors.

As the inducer of PARP-1 enzyme activity, gap DNA was prepared. To this end, 25 mg of DNA (source: Sigma) was added to DNAase buffer (10 mM Tris-HCl, pH 7.4; 0.5 mg / ml bovine serum albumin (BSA); 5 mM MgCl ₂ · 6H ₂ O and 1 mM KCl). ) Was dissolved in 25 ml, and 50 µl of DNAase solution (1 mg / ml in 0.15 M NaCl) was added thereto. After incubation at 37 ° C. for 90 minutes, the reaction was stopped by adding 1.45 g of NaCl, followed by further incubation at 58 ° C. for 15 minutes. The reaction mixture was cooled on ice and dialyzed twice at 1.5 ° C. at 1.5 L of 0.2 M KCl for 1.5 hours and 2 hours, respectively, and at 1.5 L of 0.01 M KCl for 1.5 hours and 2 hours, respectively. The mixture was divided and stored at -20 ° C. Histone (1 mg / ml, type II-A, source: Sigma) was biotinylated using Amersham Biotinylation Kit and stored at −20 ° C. in portions. Stock solutions of 100 mg / ml SPA poly (vinyl toluene) (PVT) beads (Source: Amersham) were prepared in PBS. 120 μl of [ ³ H] -NAD ⁺ (0.1 mCi / ml, source: NEN) was added to 6 ml of culture buffer (50 mM Tris / HCl, pH 8; 0.2 mM DTT; 4 mM MgCl ₂ ) [ ³ H] -NAD ⁺ stock solution was prepared. A solution of 4 mM NAD ⁺ (Source: Roche) was prepared in culture buffer (100 mM stock in water stored at -20 ° C). PARP-1 enzymes were produced using techniques known in the art, ie, cloning and expression of proteins starting from human liver cDNA. Information on the protein sequence used of the PARP-1 enzyme, including literature references, can be found in the Swiss-Prot database under primary accession number P09874. Biotinylated histones and PVT-SPA beads were mixed and preincubated for 30 minutes at room temperature. PARP-1 enzyme (concentration depends on the lot) was mixed with the gap DNA and the mixture was preincubated for 30 minutes at 4 ° C. Mix the same portion of this histone / PVT-SPA bead solution and PARP-1 enzyme / DNA solution and 75 μl of this mixture with 1 μl of compound in DMSO and 25 μl of [ ³ H] -NAD ^{+ 25} μl Each well was added to the plate. The final concentration in the culture mixture was 2 μg / ml for biotinylated histones, 2 mg / ml for PVT-SPA beads, 2 μg / ml for gap DNA and 5-10 μg / ml for PARP-1 enzymes. After the mixture was incubated for 15 minutes at room temperature, the reaction was stopped by adding 4 μl NAD ⁺ 100 μl in culture buffer (final concentration 2 mM) and the plates were mixed.

The beads were allowed to settle for at least 15 minutes and the plates transferred to TopCountNXT ™ (Packard, Inc.) for scintillation counting were expressed as cpm (counts per minute). For each experiment, a control (containing PARP-1 enzyme and DMSO without compound), blank culture (no PAP-1 enzyme or compound but containing DMSO) and sample (PARP-1 enzyme and compound dissolved in DMSO) were used. Containing) were run in parallel. All compounds tested were dissolved and ultimately further diluted in DMSO. In the first step, the compound was tested at a concentration of 10 ^-5 M. When the compound showed activity at 10 ^-5 M, when tested at concentrations between 10 ^-5 M and 10 ^-8 M dose-response curve was prepared. For each test, blank values were subtracted from both control values and sample values. Control samples showed maximum PARP-1 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the control. Where appropriate, IC ₅₀ -values (concentration of drug required to reduce PAP-1 enzyme activity to 50% of control) were calculated using linear interpolation between experimental points just above and below the 50% level. Here, the effect of the test compound was expressed as pIC ₅₀ (negative logarithm of IC ₅₀ -value). As reference compound, 4-amino-1,8-naphthalimide is included to validate the SPA assay. Compounds tested showed inhibitory activity at initial test concentrations of 10 ⁻⁵ M (see Table 2).

PARP For -1 inhibitory activity In vitro  Filtration Essay

Compounds of the present invention utilize [ ³² P] -NAD as an ADP-ribosyl donor to evaluate PARP-1 activity (initiated in the presence of gap DNA) by its histone poly (ADP-ribosyl) activity. It was tested in an in vitro filtration assay. Radioactive ribosylated histones were precipitated by trichloroacetic acid (TCA) in 96-well filterplates and the incorporated [ ³² P] was measured using a scintillation counter.

Histone (stock: 5 mg / ml in H ₂ O), NAD ⁺ (stock: 100 mM in H ₂ O) in culture buffer (50 mM Tris / HCl, pH 8; 0.2 mM DTT; 4 mM MgCl ₂ ) and [ A mixture of ³² P] -NAD ⁺ was made. A mixture of PARP-1 enzyme (5-10 μg / ml) and gap DNA was also prepared. Gap DNA was prepared as described in in vitro SPA for PARP-1 inhibitory activity. 75 μl of PARP-1 enzyme / DNA mixture and 25 μl of histone-NAD ⁺ / [ ³² P] -NAD ⁺ mixture with 1 μl of compound in DMSO were wells in a 96-well filterplate (0.45 μm, supplied by Millipore). Every time. The final concentration of the culture mixture was 2 μg / ml for histones, 0.1 mM for NAD ⁺ , 200 μM (0.5 μC) for [ ³² P] -NAD ⁺ and 2 μg / ml for gap DNA. After incubating the plate for 15 minutes at room temperature, the reaction was stopped by addition of 10 μl of ice cold 100% TCA followed by 10 μl of ice cold BSA solution (H ₂ O 1%). The protein fraction was precipitated at 4 ° C. for 10 minutes and the plate was vacuum filtered. Plates were then washed at room temperature with 1 ml of 10% ice cold TCA, 1 ml 5% ice cold TCA and 1 ml 5% TCA for each well. Finally 100 μl of scintillation solution (Microscint 40, available from Packard) was added for each well, and plates were transferred to TopCountNXT ™ (Source: Packard) for scintillation counting and values were expressed as cpm. For each experiment, a control (containing PARP-1 enzyme and DMSO without compound), blank culture (no PAP-1 enzyme or compound but containing DMSO) and sample (PARP-1 enzyme and compound dissolved in DMSO) were used. Containing) were run in parallel. All compounds tested were dissolved and ultimately further diluted in DMSO. In the first step, the compound was tested at a concentration of 10 ^-5 M. When the compound showed activity at 10 ^-5 M, when tested at concentrations between 10 ^-5 M and 10 ^-8 M dose-response curve was prepared. For each test, blank values were subtracted from both control values and sample values. Control samples showed maximum PARP-1 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the control. Where appropriate, IC ₅₀ -values (concentration of drug required to reduce PAP-1 enzyme activity to 50% of control) were calculated using linear interpolation between experimental points just above and below the 50% level. Here, the effect of the test compound was expressed as pIC ₅₀ (negative logarithm of IC ₅₀ -value). As reference compound, 4-amino-1,8-naphthalimide is included to validate the filtration assay. Compounds tested showed inhibitory activity at initial test concentrations of 10 ⁻⁵ M (see Table 2).

TANK For -2 inhibitory activity In vitro Flash  Metric (" SPA ")

Compounds of the present invention were tested in in vitro assays based on SPA techniques with Ni flash plates (96 or 384 wells).

In principle, the assay is an ADP-ribosyl donor using [ ³ H] -nicotinamide adenine dinucleotide ([ ³ H] -NAD ⁺ ) to auto-poly (ADP-ribosyl) ylation of TANK-2 protein. Rely on SPA technology for detection.

64.6 μl of [ ³ H] -NAD ⁺ (0.1 mCi / ml from Perkin Elmer) and 46.7 μl of NAD-stock (10.7 mM, preserved at −20 ° C., Roche) were assay buffer (60 mM Tris / A stock solution of [ ³ H] -NAD ⁺ / NAD was prepared by adding to 1888.7 μl of HCl, pH 7.4; 0.9 mM DTT; 6 mM MgCl ₂ ). TANK-2 enzyme was produced as described in EP 1238063. 96-well Ni-coated flash plate (Perkin) with 60 μl of assay buffer, 20 μl of [ ³ H] -NAD ⁺ / NAD and 20 μl of TANK-2 enzyme (final concentration 6 μg / ml) with 1 μl of compound in DMSO Elmer) was added per well. The mixture was incubated at room temperature for 120 minutes and then the reaction was stopped by adding 60 μl of stop solution (42.6 mg NAD in 6 mL of H ₂ O). The plate was covered with a plate sealant and placed in TopCountNXT ™ (manufactured by Packard) for scintillation counting. Values are expressed as cpm. For each experiment, the control (containing TANK-2 enzyme and DMSO without compound), blank culture (without TANK-2 enzyme or compound but containing DMSO) and sample (TANK-2 enzyme and compound dissolved in DMSO) Containing) were run in parallel. All compounds tested were dissolved and ultimately further diluted in DMSO. In the first step, the compound was tested at a concentration of 10 ^-5 M. When the compound showed activity at 10 ^-5 M, when tested at concentrations between 10 ^-5 M and 10 ^-8 M dose-response curve was prepared. For each test, blank values were subtracted from both control values and sample values. Control samples showed maximum TANK-2 enzyme activity. For each sample, the amount of cpm was expressed as a percentage of the mean cpm value of the control. Where appropriate, IC ₅₀ -values (concentration of drug required to reduce TANK-2 enzyme activity to 50% of control) were calculated using linear interpolation between experimental points just above and below the 50% level. Here, the effect of the test compound was expressed as pIC ₅₀ (negative logarithm of IC ₅₀ -value). As reference compounds, 3-aminobenzamide and 4-amino-1,8-naphthalimide are included to validate the SPA assay. Essays were described using 96-well plates. In the assay using 384-well plates the same final concentration was used and the volume was adopted. If 96-well plate results are available, these results are merged in Table 2 and the results from the 384-well plate assay are shown.

The compounds are chemical cell-in and / or a radiation sensitization assay, the cancer cell lines and eventually in vivo (in Evaluation of assay measurement inhibition of endogenous PARP-1 activity in vivo ) radiosensitization test can be further performed.

Claims (13)

A compound of formula (I), an N-oxide form thereof, a pharmaceutically acceptable addition salt or stereochemically isomeric form:

In the formula, X is each independently

or

ego; X

Y is

Is; Each Y independently

or

ego; Only X

If is Y

Except L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from; L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl -, -C (O) -C _1-6 alkanediyl - or - C _{1 - 6} alkanediyl -C (O) - it is a divalent radical selected from; R ¹ is hydrogen or hydroxy; Z is hydrogen or a radical selected from formulas (a-1) to (a-5):

Wherein, R ² are each independently hydrogen, halo or C _{1 - 6} is selected from alkyl; Provided that 1- [1-[(2S) -2-[(2R) -3,4-dihydro-2H-1-benzopyran-2-yl] -2-hydroxyethyl] -4-piperidinyl ] -2,4- (1H, 3H) -quinazolindione, 1- [2- [4- (4-fluorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione, 1- [3- [4- (4-fluorobenzoyl) -1-piperidinyl] propyl] -2,4- (1H, 3H) -quinazolindione, 3- [2- [4- (4- Chlorobenzoyl) -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione and 3- [2- [4-[(4-fluorophenyl) hydroxymethyl] -1-piperidinyl] ethyl] -2,4- (1H, 3H) -quinazolindione is not included. The compound of claim 1, wherein each X is independently

or

ego; Y is each independently

or

Is; L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from; L ² is a bond, or a carbonyl, or -C _{1 - 6} alkanediyl-is a bivalent radical selected from; R ¹ is hydrogen or hydroxy; Z is hydrogen or a radical selected from formulas (a-1), (a-2), (a-3), (a-4) or (a-5); R ² are each independently hydrogen, halo or C _{1 - 6} alkyl compound selected from. The compound of claim 1 or 2, wherein X is each

ego; Y is each

Is; L ¹ is a direct bond; L ² is a direct bond; R ¹ is hydrogen; Z is hydrogen. The compound according to claim 1, 2 or 3, wherein the compound is

. The compound according to any one of claims 1 to 4 for use as a medicament. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound as claimed in claim 1 as an active ingredient. A process for preparing the pharmaceutical composition as claimed in claim 6, wherein the pharmaceutically acceptable carrier is intimately mixed with the compound as claimed in claim 1. Use of a compound of formula (I), an N-oxide form thereof, a pharmaceutically acceptable addition salt or stereochemically isomeric form thereof, for the manufacture of a medicament for the treatment of PARP mediated diseases:

In the formula, X is each independently

or

ego; X

Y is

Is; Each Y independently

or

ego; Only X

If is Y

Except L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from; L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl -, -C (O) -C _1-6 alkanediyl - or - C _{1 - 6} alkanediyl -C (O) - it is a divalent radical selected from; R ¹ is hydrogen or hydroxy; Z is hydrogen or a radical selected from formulas (a-1) to (a-5):

Wherein, R ² are each independently hydrogen, halo or C _{1 - 6} is selected from alkyl. Use of a PARP inhibitor of formula (I) for the preparation of a medicament for the treatment of PARP-1 mediated diseases. Use according to claim 8 or 9, wherein the treatment comprises chemosensitization. Use according to claim 8 or 9, wherein the treatment comprises radiosensitization. A combination of a chemotherapeutic agent with a compound of formula (I), in its N-oxide form, in a pharmaceutically acceptable addition salt or stereochemically isomeric form:

In the formula, X is each independently

or

ego; X

Y is Is; Each Y independently

or

ego; Only X

If is Y

Except L ¹ is a direct bond or -C _{1 - 6} alkanediyl - a divalent radical selected from; L ² is a bond, or a carbonyl group, -C _{1 - 6} alkanediyl -, - (hydroxy) C _{1 - 6} alkanediyl -, -C (O) -C _1-6 alkanediyl - or - C _{1 - 6} alkanediyl -C (O) - it is a divalent radical selected from; R ¹ is hydrogen or hydroxy; Z is hydrogen or a radical selected from formulas (a-1) to (a-5):

Wherein, R ² are each independently hydrogen, halo or C _{1 - 6} is selected from alkyl. a) An intermediate of formula (II) is reacted with an intermediate of formula (III) by addition of a suitable base in a solvent inert to the reaction, where X is

To form a compound of formula (Ia); or b) reacting a compound of formula (IV) with an intermediate of formula (V) by addition of a suitable base in a solvent inert to the reaction, wherein

A process for the preparation of a compound as claimed in claim 1, characterized by forming a compound of formula (Ib): a)

; b)

In formula, W is a suitable leaving group.